<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3495">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04356495</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2020/12</org_study_id>
    <nct_id>NCT04356495</nct_id>
  </id_info>
  <brief_title>Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation</brief_title>
  <acronym>COVERAGEFrance</acronym>
  <official_title>Randomized Trial to Evaluate the Safety and Efficacy of Outpatient Treatments to Reduce the Risk of Worsening in Individuals With COVID-19 With Risk Factors (COVERAGE France)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In adults with COVID-19 without criteria for hospitalization or oxygen therapy but with risk&#xD;
      factors for aggravation, early treatment may avoid hospitalization, indication for oxygen&#xD;
      therapy or death. No treatment is currently validated for this indication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COVERAGE France is Multicenter, randomized, controlled clinical trial with for each drug :&#xD;
&#xD;
        -  A safety study pilot phase.&#xD;
&#xD;
        -  An efficacy study phase. The data collected during the pilot phase, combined with new&#xD;
           external data that emerged during the period, will be used to position treatments for&#xD;
           the efficacy phase.&#xD;
&#xD;
        -  Pilot phase will evaluate the tolerance of experimental treatments for drugs given for&#xD;
           the first time (&quot;first in home-based care&quot;) in ambulatory individuals with COVID-19 with&#xD;
           aggravating risk factors.&#xD;
&#xD;
        -  Efficacy Phase: To estimate the effectiveness of experimental ambulatory treatments,&#xD;
           compared to vitamin supplementation, in reducing the risk of hospitalization, oxygen&#xD;
           therapy indication or death in ambulatory individuals with COVID-19 with aggravating&#xD;
           risk factors.&#xD;
&#xD;
      The trial is a national platform with the vocation to open as many centers as possible,&#xD;
      subject to criteria set by the Scientific Advisory Board.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, randomized, controlled clinical trial with for each drug :&#xD;
A safety study pilot phase.&#xD;
An efficacy study phase. The data collected during the pilot phase, combined with new external data that emerged during the period, will be used to position treatments for the efficacy phase.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pilot Phase: Proportion of participants who had a Grade 3 or 4 adverse event</measure>
    <time_frame>From inclusion (day0) to day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy phase: Death</measure>
    <time_frame>From inclusion (day0) to day 14</time_frame>
    <description>Proportion of participants with an occurrence of death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy phase: oxygen therapy</measure>
    <time_frame>From inclusion (day0) to day 14</time_frame>
    <description>Proportion of participants who had an indication for oxygen therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy phase: hospitalization</measure>
    <time_frame>From inclusion (day0) to day 14</time_frame>
    <description>Proportion of participants who had an indication for hospitalization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of hospitalizations, overall and by cause, in each group</measure>
    <time_frame>From inclusion (day0) to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death and causes of death</measure>
    <time_frame>From inclusion (day0) to day 28</time_frame>
    <description>Proportion of deaths, overall and by cause, in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of intensive care hospitalizations, overall and by cause, in each group</measure>
    <time_frame>From inclusion (day0) to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with negative SARS-CoV-2 RT-PCR</measure>
    <time_frame>day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematological markers evolution</measure>
    <time_frame>from inclusion (day 0) to day 7</time_frame>
    <description>Evolution of Haematological markers in each group : Complete Blood Count, prothrombin level, INR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers evolution</measure>
    <time_frame>from inclusion (day 0) to day 7</time_frame>
    <description>Evolution of Inflammatory markers in each group : PCT, CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>from inclusion (day 0) to day 28</time_frame>
    <description>Number and proportion of grade 1,2,3,4 adverse events in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions</measure>
    <time_frame>from inclusion (day 0) to day 28</time_frame>
    <description>Number and proportion of grade 1,2,3,4 adverse events in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of the treatment</measure>
    <time_frame>from inclusion (day 0) to day 10</time_frame>
    <description>Acceptability of the treatment by participant will be assessed with an interview</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic consumption</measure>
    <time_frame>from inclusion (day 0) to day 28</time_frame>
    <description>Proportion of participants who received at least one day of antibiotic therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation worsening</measure>
    <time_frame>from inclusion (day 0) to day 28</time_frame>
    <description>Proportion of participants who experienced a worsening of oxygen saturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>protocol follow-up</measure>
    <time_frame>from inclusion (day 0) to day 10</time_frame>
    <description>Proportion of participants who completed the prescribed protocol treatment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">820</enrollment>
  <condition>Corona Virus Infection</condition>
  <condition>Sars-CoV2</condition>
  <arm_group>
    <arm_group_label>Vitamins</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients in this arm will receive a vitamin supplement (&quot;AZINC forme et vitalité®&quot;) during 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive Telmisartan (Micardis® 20 mg) during 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciclesonide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive ciclesonide (Alvesco® 160 µg ) during 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>interferon β-1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive interferon β-1b (Extavia® 9,6 MUI/300 µg ) during 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamins</intervention_name>
    <description>2 tablets daily from the first day (day 0) to day 9</description>
    <arm_group_label>Vitamins</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <description>1 tablet daily from the first day (day 0) to day 9</description>
    <arm_group_label>Telmisartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide</intervention_name>
    <description>2 puffs twice a day in an inhalation chamber from the first day (day 0) to day 9</description>
    <arm_group_label>Ciclesonide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interferon β-1b</intervention_name>
    <description>A 10-minute nebulization, once a day, from the first day (day 0) to day 4, of 9.6 MIU / 300 µg of IFN-β-1b (EXTAVIA®) diluted in 2 mL of water</description>
    <arm_group_label>interferon β-1b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical picture suggestive of COVID-19 dated 7 days or less.&#xD;
&#xD;
          -  Positivity of a test proving an acute SARS-CoV-2 infection, according to current&#xD;
             recommendations.&#xD;
&#xD;
          -  Absence of criteria for hospitalization or oxygen therapy according to current&#xD;
             recommendations.&#xD;
&#xD;
          -  Age :&#xD;
&#xD;
               -  greater than or equal to 60 years of age without any risk factor&#xD;
&#xD;
               -  or between 50 and 59 years of age and the presence of at least one of the&#xD;
                  following risk factors :&#xD;
&#xD;
                    -  Arterial hypertension under treatment (all stages)&#xD;
&#xD;
                    -  Obesity (BMI ≥30 kg/m2)&#xD;
&#xD;
                    -  Diabetes under treatment (all types)&#xD;
&#xD;
                    -  Ischemic heart disease (all stages)&#xD;
&#xD;
                    -  Heart failure (all stages)&#xD;
&#xD;
                    -  Stroke History&#xD;
&#xD;
                    -  Chronic Obstructive Pulmonary Disease (all stages)&#xD;
&#xD;
                    -  Stage 3 chronic renal failure (30 ≤ Estimated GFR &lt; 60 mL/min/1.73 m²)&#xD;
&#xD;
                    -  Malignancies (solid tumours or blood malignancies) that are progressive or&#xD;
                       were diagnosed less than 5 years ago.&#xD;
&#xD;
                    -  Immunodeficiency&#xD;
&#xD;
          -  of therapeutic origin (solid organ transplant or hematopoietic stem cell transplant,&#xD;
             cancer chemotherapy, immunosuppressive therapy, corticosteroids &gt; 15 mg/d of&#xD;
             prednisone equivalent taken for at least 2 months);&#xD;
&#xD;
          -  HIV infection with CD4&lt;200/mm3.&#xD;
&#xD;
          -  Valid, ambulatory person, fully able to understand the issues of the trial&#xD;
&#xD;
          -  Beneficiary of a Social Security scheme&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Asymptomatic person&#xD;
&#xD;
          -  Inability to make a decision to participate (dementia, person under legal protection,&#xD;
             curatorship or guardianship)&#xD;
&#xD;
          -  Ongoing illness or chronic treatment contraindicated by taking one of the trial drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis MALVY, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xavier ANGLARET, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Inserm 1219</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura RICHERT, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Denis MALVY, Pr</last_name>
    <phone>0557822796</phone>
    <phone_ext>+33</phone_ext>
    <email>denis.malvy@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xavier ANGLARET, Dr</last_name>
    <phone>0557571258</phone>
    <phone_ext>+33</phone_ext>
    <email>xavier.anglaret@u-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH de Bastia</name>
      <address>
        <city>Bastia</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas DARNAUD, Dr</last_name>
      <email>thomas.darnaud@ch-bastia.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bordeaux university Hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre DUVIGNAUD, Dr</last_name>
      <email>alexandre.duvignaud@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Xavier ANGLARET, Dr</last_name>
      <phone>0557571258</phone>
      <phone_ext>+33</phone_ext>
      <email>xavier.anglaret@u-bordeaux.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon-Bourgogne</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel PIROTH, Pr</last_name>
      <email>lionel.piroth@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain MAKINSON, Dr</last_name>
      <email>a-makinson@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin LEFEVRE, Dr</last_name>
      <email>B.LEFEVRE@chru-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe hospitalier Paris Saint Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Marc NACCACHE, Dr</last_name>
      <email>jmnaccache@ghpsj.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IMEA</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roland LANDMAN, Dr</last_name>
      <email>landman.roland@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie DUPOUY, Dr</last_name>
      <email>julie.dupouy@dumg-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 11, 2020</study_first_submitted>
  <study_first_submitted_qc>April 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Corona virus</keyword>
  <keyword>Sars-CoV2</keyword>
  <keyword>telmisartan</keyword>
  <keyword>ciclesonide</keyword>
  <keyword>interferon β-1b</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciclesonide</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Interferon beta-1b</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

